A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
NCT05877820
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Fumarate Hydratase Deficient Renal Cell Carcinoma
Interventions
BIOLOGICAL:
Tislelizumab
DRUG:
Lenvatinib
Sponsor
RenJi Hospital